Skip to main content

Table 1 Clinicopathologic characteristics of all patients

From: Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma

Characteristics All
(n = 338, %)
At the time of diagnosis
 FIGO stage
  IC 19 (5.6)
  II 29 (8.6)
  III 169 (50.0)
  IV 121 (35.8)
 Initial serum CA-125 a, IU/ml
  Median (IQR) 878.0 (289.0–2433.0)
 Primary treatment strategy
  Primary debulking surgery 225 (66.6)
  Neoadjuvant chemotherapy 113 (33.4)
At the time of surgery
 Age, years
  Mean ± SD 57.8 ± 11.2
 BMI, kg/m2
  Median (IQR) 23.2 (20.9–25.4)
  Underweight (<18.5) 24 (7.1)
  Normal (18.5–22.9) 134 (39.6)
  Overweight (23.0–24.9) 81 (24.0)
  Obesity (≥25.0) 99 (29.3)
 Comorbidities
  Hypertension 58 (17.2)
  Diabetes 19 (5.6)
  Liver disease 7 (2.1)
  Heart disease 9 (2.7)
  Renal disease 2 (0.6)
  Vascular disease 2 (0.6)
  Neurologic disease 5 (1.5)
  Asthma 2 (0.6)
 ASA classification
  1 65 (19.2)
  2 220 (65.1)
  3 52 (15.4)
  4 1 (0.3)
 Surgical complexity score
  Median (IQR) 6 (4–9)
  Low (≤3) 33 (9.8)
  Intermediate (4–7) 175 (51.8)
  High (≥8) 130 (38.5)
 Residual tumor after PDS/IDS
  Complete cytoreduction (R0) 253 (74.9)
   < 1 cm 48 (14.2)
  1–2 cm 22 (6.5)
   ≥ 2 cm 15 (4.4)
  1. Abbreviations: ASA American Society of Anesthesiologists, BMI Body mass index, CA-125 Cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, IDS Interval debulking surgery, IQR Interquartile range, SD Standard deviation
  2. Missing data: a 3